Program Description
Our Investigator-Sponsored Trials (IST) program provides support for external clinical research that advances medical and/or scientific knowledge about our products and clinical candidates to enhance patient care. Our current IST portfolio includes programs investigating:
The objective of our IST program is to provide funding and/or study drug for clinical research that will:
Innovation to Achieve Equity in Cancer Care IST
Seagen is committed to improving the lives of people with cancer through innovative therapies in a diverse, equitable and inclusive manner. Recognizing that cancer health disparities persist, to achieve our mission of making meaningful differences in the lives of people with cancer, we are inviting you to propose and submit a concept to research actionable solutions to address health disparities.
Please click here for a complete description of the RFP. Please click here to access the portal for concept submission.
To discuss your proposed research or for questions about our process, please contact your regional Medical Science Liaison (MSL) or email us at IST@seagen.com for help identifying the MSL in your region.
Process Outline
New IST Concept Submission Deadlines
Spring Review |
Feb 15, 2023 |
Summer Review |
June 15, 2023 |
Fall Review |
Oct 2, 2023 |
For a detailed description of our program, processes, and applicant responsibilities, click Program Overview.
Application and Questions
To apply for an IST related to brentuximab vedotin, tucatinib, enfortumab vedotin (Canada only), or tisotumab vedotin (North America and EU-16 countries only), please submit your concept in our online portal.
Enfortumab vedotin
To apply for an IST related to enfortumab vedotin research (United States only), please visit the Astellas Investigator-Sponsored Research portal. Enfortumab vedotin proposals from United States investigators are reviewed jointly by Seagen and Astellas.
Tisotumab vedotin
To apply for an IST related to tisotumab vedotin research (Japan only), please visit the Genmab Investigator-Sponsored Research portal. All tisotumab vedotin proposals are reviewed jointly by Seagen and Genmab.
Please email IST@seagen.com with questions about our IST program.
Program Description
Our Translational Research Agreement (TRA) program provides support for non-clinical research projects.
Requests for materials transfer or sponsored research will be considered, with a limited number of projects supported each year. To discuss your proposed research or for questions about our process, please contact your regional Medical Science Liaison (MSL) or email us at translationalresearch@seagen.com for help identifying the MSL in your region.
Process Outline
Project will be reviewed within 90 days and the regional MSL will present the proposal internally.
For questions regarding our process, email us at translationalresearch@seagen.com.
Application and Questions
To apply for a TRA related to available programs and for enfortumab vedotin (Canada only), please submit your concept in our online portal. All tisotumab vedotin proposals are reviewed jointly by Seagen and Genmab.
To apply for a TRA related to enfortumab vedotin research (United States only), please visit the Astellas Investigator-Sponsored Research portal. Enfortumab vedotin proposals from United States investigators are reviewed jointly by Seagen and Astellas.
Please email translationalresearch@seagen.com with questions about our TRA program.
Healthcare professionals in the United States can access recent congress presentations, videos about our science, and more on our medical affairs website.